A Phase 4, Double-Blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With OAB Symptoms, While Taking the Alpha Blocker,Tamsulosin, for BPH
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 11 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Planned End Date changed from 31 Aug 2017 to 1 Aug 2018.